Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis Impact of Timing of Treatment Initiation

Toby M Maher (1) , Lisa H Lancaster (2) , Stéphane Jouneau (3) , Lake Morrison (4) , David J Lederer (5) , Maria Molina-Molina (6, 7) , Elisabeth Bendstrup (8) , Klaus-Uwe Kirchgaessler (9) , Frank Gilberg (9) , Judit Axmann (9) , Ute Petzinger , Paul W Noble (10)

1 Imperial College London
2 Vanderbilt University Medical Center [Nashville]
3 Irset - Institut de recherche en santé, environnement et travail
4 Duke University Medical Center
5 CUMC - Columbia University Medical Center
6 IDIBELL - Institut d'Investigació Biomèdica de Bellvitge = Bellvitge Biomedical Research Institute
7 CIBERES - Centro de Investigación Biomédica en Red Enfermedades Respiratorias
8 Aarhus University Hospital
9 F. Hoffmann-La Roche [Basel]
10 Cedars-Sinai Medical Center

Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, fatal, fibrosing lung disease. Pirfenidone and nintedanib are oral antifibrotics with demonstrated efficacy in reducing lung function decline in individuals with IPF, independent of baseline lung function. Intervention with an antifibrotic as early as possible in the disease course might be the most appropriate strategy to preserve lung capacity. However, many physicians are reluctant to initiate antifibrotics at diagnosis, and delay treatment until disease progression is observed. Furthermore, certain countries do not reimburse antifibrotic treatment for individuals with preserved lung function (% predicted forced vital capacity [FVC] > 80%). These post hoc analyses aimed to assess: 1) FVC decline during long-term pirfenidone treatment in RECAP in individuals with IPF categorized by baseline % predicted FVC; and 2) the impact of deferring pirfenidone treatment on annual FVC decline in individuals with IPF during CAPACITY and RECAP.

Domaines: Immunothérapie; Pneumologie et système respiratoire

Toby M Maher, Lisa H Lancaster, Stéphane Jouneau, Lake Morrison, David J Lederer, et al.. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, 16 (7), pp.927-930. ⟨10.1513/AnnalsATS.201810-720RL⟩. ⟨hal-02119171⟩